Vir Biotechnology, Inc. (NASDAQ:VIR) Director Janet Napolitano Sells 12,190 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Janet Napolitano sold 12,190 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total transaction of $95,082.00. Following the completion of the sale, the director now directly owns 11,616 shares of the company’s stock, valued at $90,604.80. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Vir Biotechnology Trading Up 2.0 %

Shares of Vir Biotechnology stock opened at $7.98 on Wednesday. The company’s 50-day moving average price is $8.94 and its 200-day moving average price is $9.56. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -1.99 and a beta of 0.47. Vir Biotechnology, Inc. has a 12-month low of $7.41 and a 12-month high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, August 1st. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.13). The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.53 million. Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. The business’s revenue for the quarter was down 19.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.45) earnings per share. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current year.

Institutional Investors Weigh In On Vir Biotechnology

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Vir Biotechnology by 9.8% in the 4th quarter. Vanguard Group Inc. now owns 12,297,139 shares of the company’s stock worth $123,709,000 after buying an additional 1,096,473 shares in the last quarter. ProShare Advisors LLC increased its stake in Vir Biotechnology by 8.4% in the first quarter. ProShare Advisors LLC now owns 26,392 shares of the company’s stock valued at $267,000 after acquiring an additional 2,035 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Vir Biotechnology by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,073 shares of the company’s stock valued at $7,576,000 after purchasing an additional 31,405 shares in the last quarter. Quest Partners LLC purchased a new stake in Vir Biotechnology during the fourth quarter valued at about $258,000. Finally, Empowered Funds LLC lifted its stake in Vir Biotechnology by 8.2% during the first quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock worth $4,640,000 after purchasing an additional 34,640 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on VIR. Morgan Stanley boosted their price objective on Vir Biotechnology from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 6th. Barclays upped their price objective on Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Needham & Company LLC raised their target price on Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, June 5th. Finally, HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.80.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.